Abrysvo Or Arexvy Market Report 2026

Abrysvo Or Arexvy Market Overview

• The Abrysvo Or Arexvy market growth in the historic period has been driven by unmet need for rsv vaccines, aging population growth • Market expansion is supported by expanding elderly demographics, rising rsv hospitalization rates • Growth Driver: The Prevalence Of RSV Infections Drives Demand For Abrysvo Vaccine • Market Trend: Advancements In Vaccine Technology Enhance RSV Vaccine Development • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Abrysvo Or Arexvy Market?

Abrysvo (also known as arexvy) is a vaccine developed for the prevention of respiratory syncytial virus (RSV) in adults aged 60 and older. It is designed to reduce the risk of severe illness caused by RSV, which can lead to respiratory complications in older adults. The main clinical indications in the abrysvo or arexvy market are respiratory syncytial virus (RSV) prevention and infant protection. RSV prevention refers to the use of medical treatments or vaccines aimed at reducing the risk of infection by the respiratory syncytial virus, which can lead to serious respiratory problems, especially in infants, the elderly, and those with weakened immune systems. The various age groups include adults (18-59 years), older adults (60+ years), and pregnant individuals (32-36 weeks of gestation), and several end users including healthcare providers, pregnant individuals, and high-risk adults.

What Is The Abrysvo Or Arexvy Market Growth Forecast?

The growth in the forecast period can be attributed to expanding elderly demographics, rising rsv hospitalization rates, broader vaccination recommendations, improved access through providers, preventive healthcare focus. Major trends in the forecast period include growing focus on rsv prevention, rising vaccination in older adults, expansion of adult immunization programs, hospital and community vaccine delivery, preventive care for high risk populations.

Global Abrysvo Or Arexvy Market Segmentation

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prevention, Infant Protection 2) By Age Group: Adults (18-59 years), Older Adults (60+ years), Pregnant Individuals (32-36 weeks of gestation) 3) By End User: Healthcare Providers, Pregnant Individuals, High-Risk Adults

What Are The Drivers Of The Abrysvo Or Arexvy Market?

The increasing prevalence of respiratory syncytial virus (RSV) infections is expected to propel the growth of the abrysvo or arexvy market going forward. RSV infections are caused by the respiratory syncytial virus, a common virus that primarily affects the respiratory tract, leading to mild cold-like symptoms in most individuals but potentially severe illness in infants, older adults, and immunocompromised individuals. The increasing prevalence of RSV infections is driven by its highly contagious nature, seasonal outbreaks, lack of widespread immunity, and increased susceptibility among vulnerable populations such as infants and the elderly. Abrysvo helps address the prevalence of RSV infections by providing targeted vaccines that protect high-risk populations, such as older adults and infants, from severe respiratory syncytial virus-related illnesses. For instance, in Oct 2024, according to the Centers for Disease Control and Prevention, a US-based health protection agency, during the 2024-25 season, the overall rate of hospitalizations associated with RSV reached 3.2 per 100,000 individuals. Therefore, the prevalence of RSV infections drives the growth of the abrysvo or arexvy industry. The rise in healthcare expenditure is expected to propel the growth of the abrysvo or arexvy market going forward. Healthcare expenditure is attributed to the financial investment made by governments, private insurers, and individuals in the healthcare system to improve and expand medical services. The rise in healthcare expenditure is due to factors such as an aging population, advancements in medical technology, increased prevalence of chronic diseases, higher demand for healthcare services, and rising costs of pharmaceuticals and treatments. Healthcare expenditure helps the abrysvo or arexvy by increasing the financial resources allocated to advanced treatment options, including biologic therapies. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, rise in healthcare expenditure is driving the growth of the abrysvo or arexvy industry.

Key Players In The Global Abrysvo Or Arexvy Market

Major companies operating in the abrysvo or arexvy market are Pfizer Inc., GlaxoSmithKline plc (GSK)

Global Abrysvo Or Arexvy Market Trends and Insights

Major companies operating in the abrysvo or arexvy market are focusing on developing advanced products, such as bivalent prefusion F (RSVpreF) vaccines, to broaden protection, enhance safety, and address high-risk populations. Bivalent RSVpreF vaccines refer to formulations designed to provide immunity against both major RSV subgroups (RSV-A and RSV-B) by targeting the prefusion state of the fusion (F) protein, a key site for neutralizing antibodies. For instance, in October 2024, Pfizer Inc., a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for ABRYSVO (RSV Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract disease in adults aged 18 to 59 at increased risk, expanding its indication to the broadest adult population. It remains the only approved RSV vaccine for pregnant individuals between 32 and 36 weeks of gestation to protect infants from birth to 6 months.

Regional Insights

North America was the largest region in the abrysvo or arexvy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Abrysvo Or Arexvy Market?

The abrysvo or arexvy market consists of sales of prefilled syringes, vaccine vials, vaccine storage equipment, syringes, and needles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Abrysvo Or Arexvy Market Report 2026?

The abrysvo or arexvy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the abrysvo or arexvy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.